Untitled

Core Pharmacology Learning Objectives

  • Comprehensive Drug Knowledge Requirements:
    • For every antimicrobial agent, mastery of the following specific domains is required:
    • Class: Taxonomic and chemical categorization of the drug.
    • Activity: Spectrum of antimicrobial efficacy (e.g., broad-spectrum vs. narrow-spectrum; bactericidal vs. bacteriostatic).
    • Mechanism of Action (MOA): Precise biochemical and physiological molecular target within the bacterial cell.
    • Resistance Mechanisms: Biochemical, structural, or enzymatic adaptations bacteria utilize to evade drug efficacy (e.g., target modification, drug inactivation, active efflux, reduced membrane permeability).
    • Target Bacteria: Specific clinical pathogens, Gram-positive and Gram-negative species, aerobes, and anaerobes susceptible to the agent.

Overview of Antimicrobial Cellular Targets

Overview of bacterial cell targets and antimicrobial mechanisms of action

  • Bacterial Structural and Functional Target Categories:
    • Cell Wall Synthesis: Targeting enzymes and structural precursors necessary for the synthesis and cross-linking of the peptidoglycan cell wall.
    • Cell Membrane Integrity: Alteration and disruption of the permeability and physical structure of bacterial lipid membranes.
    • Folic Acid Metabolism: Selective disruption of the enzymatic de novo folate synthesis pathway required for bacterial survival.
    • DNA Replication: Interruption of topological maintenance and uncoiling of bacterial DNA by inhibiting topoisomerases like DNA gyrase.
    • DNA-Dependent RNA Polymerase: Interruption of messenger RNA (mRNA) transcription from genomic DNA.
    • Protein Synthesis (50S50\text{S} and 30S30\text{S} Ribosomal Subunits): Targeted inhibition of translation machinery via selective binding to unique bacterial ribosomal subunits.

Cell Wall Synthesis Inhibitors

  • Biochemical Target: Peptidoglycan cell wall assembly, precursor transport, and transpeptidation reactions.
  • Key Therapeutic Agents:
    • Cycloserine: Inhibits early-stage cell wall synthesis by blocking enzymes involved in the formation of the D-alanyl-D-alanine dipeptide precursor.
    • Vancomycin (Glycopeptide class): Binds directly to the D-Ala-D-Ala terminus of cell wall peptidoglycan precursors, sterically blocking transglycosylation and transpeptidation cross-linking.
    • Bacitracin: Interferes with the dephosphorylation and recycling of the lipid carrier undecaprenyl pyrophosphate (bactoprenol), preventing transport of peptidoglycan monomer subunits across the cytoplasmic membrane.
    • Fosfomycin: Inhibits cytosolic enolpyruvyl transferase (MurA), halting the initial commitment step in bacterial peptidoglycan biosynthesis.
    • Penicillins (Beta-Lactam class): Inactivate membrane-bound penicillin-binding proteins (PBPs), preventing transpeptidation cross-linking of adjacent peptidoglycan strands.
    • Cephalosporins (Beta-Lactam class): Contain a beta-lactam core fused to a dihydrothiazine ring; selectively bind PBPs to inhibit final transpeptidation and activate bacterial autolytic enzymes.
    • Monobactams (Beta-Lactam class): Monocyclic beta-lactam core targeting specific PBPs (primarily PBP3 in aerobic Gram-negative bacilli).
    • Carbapenems (Beta-Lactam class): Ultra-broad-spectrum beta-lactams resistant to many beta-lactamases; avidly bind multiple PBPs to halt peptidoglycan cell wall synthesis.

Disruption of the Cell Membrane

  • Biochemical Target: Structural lipid bilayers of the inner and outer bacterial membranes.
  • Key Therapeutic Agents:
    • Polymyxins:
    • Act as cationic detergents.
    • Selectively bind to the negatively charged lipopolysaccharide (LPS) molecules within the outer membrane of Gram-negative bacteria.
    • Disrupt membrane architectural integrity, leading to membrane permeabilization, cellular content leakage, and rapid cell lysis.

Antimetabolites: Folic Acid Metabolism Inhibitors

  • Biochemical Target and Pathway Sequence:
    • Bacteria cannot utilize exogenous folate and must synthesize tetrahydrofolic acid (THF A\text{THF A}) de novo to produce essential purine and pyrimidine nucleotides for DNA and RNA replication.
    • Pathway Progression:
    • Step 1: Para-aminobenzoic acid (PABA\text{PABA}) is converted to Dihydrofolate (DHF A\text{DHF A}).
    • Step 2: Dihydrofolate (DHF A\text{DHF A}) is enzymatically converted to Tetrahydrofolate (THF A\text{THF A}).
    • Step 3: Tetrahydrofolate (THF A\text{THF A}) donates single-carbon units to synthesize critical nucleotides required for nucleic acid replication.
  • Site-Specific Enzymatic Inhibitors:
    • Sulfonamides: Structural analogues of PABA\text{PABA} that competitively inhibit the upstream enzyme dihydropteroate synthase in the conversion of PABA\text{PABA} to DHF A\text{DHF A}.
    • Trimethoprim: Competitively inhibits the downstream enzyme dihydrofolate reductase in the enzymatic reduction of DHF A\text{DHF A} to THF A\text{THF A}.

Nucleic Acid Synthesis Inhibitors

  • DNA Replication (DNA Gyrase Target):
    • Biological Target: Bacterial type II topoisomerase (DNA gyrase), an essential enzyme that introduces negative supercoils and relieves positive torsional strain during replication fork advancement.
    • Key Therapeutic Agents:
    • Nalidixic Acid: First-generation quinolone prototype that binds and traps the cleavage complex of bacterial DNA gyrase.
    • Quinolones / Fluoroquinolones: Inhibit DNA gyrase (in Gram-negative organisms) and topoisomerase IV (in Gram-positive organisms), inducing lethal double-stranded DNA breaks and interrupting cellular replication.
  • DNA-Dependent RNA Polymerase (Transcription Target):
    • Biological Target: The beta-subunit of bacterial DNA-dependent RNA polymerase.
    • Key Therapeutic Agent:
    • Rifampin: Binds directly to DNA-dependent RNA polymerase, blocking the nascent RNA exit channel to arrest the transcription of genomic DNA into messenger RNA (mRNA\text{mRNA}).

Protein